Two Old Drugs, One Powerful Strategy: Another Way to Reduce Cancer Recurrence
When people hear that two inexpensive, decades-old drugs can prevent cancer recurrence and metastasis, it sounds too good to be true. But in recent cancer news, a clinical trial using everolimus (EVE) and hydroxychloroquine (HCQ) showed something remarkable: zero breast cancer recurrence after three years in patients with known microscopic residual disease in the bone marrow. For cancer patients worried about cancer remission, metastases, and recurrence, this alternative cancer treatment is worth understanding—carefully and honestly.
Metastasis and Why Recurrence Happens
After primary treatment removes a tumor, small clusters or single cancer cells can remain behind in other tissues, the bone marrow, or circulation. These micro-metastases are what later grow into lung metastases, brain metastases, prostate metastases, or recurrent breast cancer. That’s why modern oncology focuses not just on shrinking tumors, but on preventing metastasis and cancer recurrence.
How Everolimus Disrupts Cancer Growth
Everolimus targets mTOR, one of the central metabolic control hubs inside cancer cells. mTOR regulates growth, protein production, and cellular survival. When mTOR is blocked, cancer cells struggle to grow and divide. That’s why everolimus has been approved in multiple cancers since 2009, including kidney cancer and some forms of breast cancer treatment. However, cancer cells often adapt and develop resistance to EVE, using alternative survival pathways.
How Hydroxychloroquine Blocks Cancer Escape
Hydroxychloroquine (HCQ) blocks autophagy, the recycling system cancer cells use when resources are limited. When everolimus cuts off growth signals, tumors turn to autophagy to survive. HCQ shuts that escape door. Together, everolimus and hydroxychloroquine trap cancer cells metabolically, preventing them from recovering.
This combination has already shown benefit in earlier kidney cancer trials by slowing tumor growth. The new breast cancer study applied it specifically to metastasis prevention instead of tumor shrinkage—and that’s why the results were so dramatic.
Why This Matters Beyond Breast Cancer
mTOR dysregulation occurs across nearly all cancers, from GBM to lung cancer and prostate cancer. Because this pathway is so central to cancer biology, this strategy should apply to many tumor types. That makes it one of the most promising complementary and alternative medicine approaches to cancer recurrence we’ve seen.
The Critical Immunotherapy Warning
There is one major caveat: both EVE and HCQ are immunosuppressive. Everolimus was originally developed as a transplant drug, and HCQ is used for autoimmune disease. That means this approach cannot be combined with cancer immunotherapy such as checkpoint inhibitors. It also conflicts with immune-boosting strategies like low-dose aspirin or fever-mimicking therapies.
For patients not using immunotherapy, however, this strategy stacks well with chemotherapy, radiation, targeted drugs, and hormone therapy.
A Promising but Nuanced Option
This was a small phase 2 study, and larger trials are needed. Still, the biological logic is strong, and the early clinical data fits decades of research on cancer metabolism and metastasis.
Used correctly, this may be one of the most powerful tools we have today to support continued cancer remission—especially after primary treatment is complete.
Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.